Risk and incidence of endocrine immune-related adverse effects under checkpoint inhibitor mono- or combination therapy in solid tumors: a meta-analysis of randomized controlled trials
Few meta-analyses on incidence of endocrine immune-related adverse effects (eirAEs) have been published and many trials have been published since.We performed a comprehensive meta-analysis with updated literature to assess risk and incidence of eirAEs of any grade and grade 3 to 5 by immune checkpoi...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
April 2024
|
| In: |
The journal of clinical endocrinology & metabolism
Year: 2024, Jahrgang: 109, Heft: 4, Pages: 1132–1144 |
| ISSN: | 1945-7197 |
| DOI: | 10.1210/clinem/dgad670 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1210/clinem/dgad670
|
| Verfasserangaben: | Irfan Vardarli, Susanne Tan, Tim Brandenburg, Frank Weidemann, Rainer Görges, Ken Herrmann, and Dagmar Führer |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1871573270 | ||
| 003 | DE-627 | ||
| 005 | 20240621101151.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231129s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1210/clinem/dgad670 |2 doi | |
| 035 | |a (DE-627)1871573270 | ||
| 035 | |a (DE-599)KXP1871573270 | ||
| 035 | |a (OCoLC)1425209105 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Vardarli, Irfan |e VerfasserIn |0 (DE-588)1259852857 |0 (DE-627)1806964759 |4 aut | |
| 245 | 1 | 0 | |a Risk and incidence of endocrine immune-related adverse effects under checkpoint inhibitor mono- or combination therapy in solid tumors |b a meta-analysis of randomized controlled trials |c Irfan Vardarli, Susanne Tan, Tim Brandenburg, Frank Weidemann, Rainer Görges, Ken Herrmann, and Dagmar Führer |
| 264 | 1 | |c April 2024 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 29.11.2023 | ||
| 520 | |a Few meta-analyses on incidence of endocrine immune-related adverse effects (eirAEs) have been published and many trials have been published since.We performed a comprehensive meta-analysis with updated literature to assess risk and incidence of eirAEs of any grade and grade 3 to 5 by immune checkpoint inhibitor (ICI) monotherapy or combination therapy in solid tumors.An electronic search using PubMed/Medline, Embase, and the Cochrane Library was performed. Randomized controlled studies (RCTs) assessing eirAEs under ICI monotherapy or ICI combination therapy were selected. Stata software (v17) was used for statistical analyses and risk of bias was evaluated using Review Manager version 5.3.A total of 69 RCTs with 80 independent reports, involving 42 886 patients, were included in the study. Meta-analysis revealed the following pooled estimates for risk ratio and incidence, respectively: for any grade hypothyroidism 7.81 (95% CI, 5.68-10.74, P < .0001) and 7.64% (95% CI, 6.23-9.17, P < .0001); significantly increased also for hyperthyroidism, hypophysitis/hypopituitarism, and adrenal insufficiency; and for insulin-dependent diabetes mellitus 1.52 (95% CI, 1.07-2.18, P = .02), and 0.087% (95% CI, 0.019-0.189, P = .0006), respectively. Meta-regression showed that combination of ICIs (nivolumab plus ipilimumab; durvalumab plus tremelimumab) is an independent risk factor for any grade hypophysitis/hypopituitarism, and that ICI agent is an independent factor of risk for adrenal insufficiency, but that cancer type is not an independent risk factor for eirAEs.We showed that risk, independent from cancer type, and incidence of eirAEs are substantially increased with ICI therapy. Combination of ICIs increases risk for eirAEs, especially for hypophysitis/hypopituitarism. | ||
| 700 | 1 | |a Tan, Susanne |d 1977- |e VerfasserIn |0 (DE-588)133277704 |0 (DE-627)539655562 |0 (DE-576)299743578 |4 aut | |
| 700 | 1 | |a Brandenburg, Tim Niclas |d 1991- |e VerfasserIn |0 (DE-588)1214307086 |0 (DE-627)1725256134 |4 aut | |
| 700 | 1 | |a Weidemann, Frank |e VerfasserIn |4 aut | |
| 700 | 1 | |a Görges, Rainer |e VerfasserIn |0 (DE-588)1247779602 |0 (DE-627)1782392556 |4 aut | |
| 700 | 1 | |a Herrmann, Ken |d 1977- |e VerfasserIn |0 (DE-588)132906481 |0 (DE-627)528411934 |0 (DE-576)299494438 |4 aut | |
| 700 | 1 | |a Führer, Dagmar |d 1969- |e VerfasserIn |0 (DE-588)11496629X |0 (DE-627)479151091 |0 (DE-576)177631538 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of clinical endocrinology & metabolism |d Oxford : Oxford University Press, 1941 |g 109(2024), 4 vom: Apr., Seite 1132–1144 |h Online-Ressource |w (DE-627)323606261 |w (DE-600)2026217-6 |w (DE-576)094425523 |x 1945-7197 |7 nnas |a Risk and incidence of endocrine immune-related adverse effects under checkpoint inhibitor mono- or combination therapy in solid tumors a meta-analysis of randomized controlled trials |
| 773 | 1 | 8 | |g volume:109 |g year:2024 |g number:4 |g month:04 |g pages:1132–1144 |g extent:13 |a Risk and incidence of endocrine immune-related adverse effects under checkpoint inhibitor mono- or combination therapy in solid tumors a meta-analysis of randomized controlled trials |
| 787 | 0 | 8 | |i Forschungsdaten |a Vardarli, Irfan |t Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors |d Heidelberg : Universität, 2023 |h 1 Online-Ressource (68 Files) |w (DE-627)187157188X |
| 856 | 4 | 0 | |u https://doi.org/10.1210/clinem/dgad670 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20231129 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 1259852857 |a Vardarli, Irfan |m 1259852857:Vardarli, Irfan |d 60000 |e 60000PV1259852857 |k 0/60000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1871573270 |e 4421672637 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"Risk and incidence of endocrine immune-related adverse effects under checkpoint inhibitor mono- or combination therapy in solid tumors","title":"Risk and incidence of endocrine immune-related adverse effects under checkpoint inhibitor mono- or combination therapy in solid tumors","subtitle":"a meta-analysis of randomized controlled trials"}],"language":["eng"],"physDesc":[{"extent":"13 S."}],"id":{"eki":["1871573270"],"doi":["10.1210/clinem/dgad670"]},"note":["Gesehen am 29.11.2023"],"relHost":[{"pubHistory":["1.1941 -"],"title":[{"title_sort":"journal of clinical endocrinology & metabolism","title":"The journal of clinical endocrinology & metabolism","subtitle":"JCEM"}],"language":["eng"],"part":{"year":"2024","text":"109(2024), 4 vom: Apr., Seite 1132–1144","volume":"109","issue":"4","pages":"1132–1144","extent":"13"},"recId":"323606261","origin":[{"publisherPlace":"Oxford ; Bethesda, Md.","publisher":"Oxford University Press ; Endocrine Society","dateIssuedDisp":"1941-","dateIssuedKey":"1941"}],"titleAlt":[{"title":"JCEM"},{"title":"The Journal of clinical endocrinology"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"physDesc":[{"extent":"Online-Ressource"}],"disp":"Risk and incidence of endocrine immune-related adverse effects under checkpoint inhibitor mono- or combination therapy in solid tumors a meta-analysis of randomized controlled trialsThe journal of clinical endocrinology & metabolism","id":{"issn":["1945-7197"],"zdb":["2026217-6"],"eki":["323606261"]},"corporate":[{"role":"isb","display":"Endocrine Society"}],"note":["Gesehen am 30.03.2017"],"name":{"displayForm":["Endocrine Society"]}}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1871573270","origin":[{"dateIssuedDisp":"April 2024","dateIssuedKey":"2024"}],"person":[{"given":"Irfan","role":"aut","display":"Vardarli, Irfan","family":"Vardarli"},{"family":"Tan","given":"Susanne","role":"aut","display":"Tan, Susanne"},{"family":"Brandenburg","role":"aut","given":"Tim Niclas","display":"Brandenburg, Tim Niclas"},{"role":"aut","given":"Frank","display":"Weidemann, Frank","family":"Weidemann"},{"family":"Görges","given":"Rainer","role":"aut","display":"Görges, Rainer"},{"family":"Herrmann","role":"aut","given":"Ken","display":"Herrmann, Ken"},{"display":"Führer, Dagmar","role":"aut","given":"Dagmar","family":"Führer"}],"name":{"displayForm":["Irfan Vardarli, Susanne Tan, Tim Brandenburg, Frank Weidemann, Rainer Görges, Ken Herrmann, and Dagmar Führer"]}} | ||
| SRT | |a VARDARLIIRRISKANDINC2024 | ||